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Inhibiting the two‑component 
system GraXRS with verteporfin 
to combat Staphylococcus aureus 
infections
Juana María Prieto1, Beatriz Rapún‑Araiz2, Carmen Gil2, José R. Penadés3, Iñigo Lasa2 & 
Cristina Latasa1*
Infections caused by Staphylococcus aureus pose a serious and sometimes fatal health issue. With the 
aim of exploring a novel therapeutic approach, we chose GraXRS, a Two‑Component System (TCS) 
that determines bacterial resilience against host innate immune barriers, as an alternative target 
to disarm S. aureus. Following a drug repurposing methodology, and taking advantage of a singular 
staphylococcal strain that lacks the whole TCS machinery but the target one, we screened 1.280 off‑
patent FDA‑approved drug for GraXRS inhibition. Reinforcing the connection between this signaling 
pathway and redox sensing, we found that antioxidant and redox‑active molecules were capable of 
reducing the expression of the GraXRS regulon. Among all the compounds, verteporfin (VER) was 
really efficient in enhancing PMN‑mediated bacterial killing, while topical administration of such drug 
in a murine model of surgical wound infection significantly reduced the bacterial load. Experiments 
relying on the chemical mimicry existing between VER and heme group suggest that redox active 
residue C227 of GraS participates in the inhibition exerted by this FDA‑approved drug. Based on these 
results, we propose VER as a promising candidate for sensitizing S. aureus that could be helpful to 
combat persistent or antibiotic‑resistant infections.
Though the undeniable efficiency of anti-infective measures like vaccines and antimicrobials have made us believe 
that infectious diseases are nowadays under control, nothing could be further from the truth. An increasing 
number of studies alert that unless actions are taken, infections caused by antibiotic-resistant bacteria will kill 
an extra 10 million people a year worldwide by  20501.
Staphylococcus aureus is one of the bacterial species whose manage is especially challenging due to the emer-
gence of methicillin-resistant (MRSA) strains. With a population-weighted mean of invasive MRSA strains of 
about 17% in terms of European  prevalence2, the major health care concern related to MRSA incidence lies in 
the limitations of currently approved treatments, which, in turn, leads to high rates of morbidity and mortality 
even in industrialized nations.
Despite of being an inoffensive colonizer of the nasal epithelium of one-third of the general  population3, 
Staphylococcus aureus might become a dangerous life-threatening pathogen when it defeats host immune sys-
tem, crosses the epithelial barrier and get access to deeper tissues like blood, dermis, gastrointestinal tract, heart 
valves or  bones3,4. This biological versatility is based on a highly orchestrated regulation of circuits that sense 
a plethora of environmental signals and modulate gene expression for fine tuning crucial traits like cell-wall 
structure, biofilm formation or resistance to antibiotics. The core feature of such circuits is the two-component-
signaling transduction system (TCS)5, which is actually one of the most conserved and effective mechanisms 
in nature for coupling external stimuli and gene expression. In its most basic form, a canonical TCS normally 
consists of a membrane-bound histidine kinase and a cytosolic response regulator that, once phosphorylated, 
elicit appropriate changes in the cell by regulating gene expression, protein interactions, or enzymatic  activity6.
Over the last decade, the scientific community has gained in-depth knowledge of the genes affected by specific 
staphylococcal TCSs, giving rise to a vast body of bibliography and information about mutants in the respective 
sensor kinases, response regulators and auxiliary genes. Thus, the pivotal role of AgrCA and SaeRS TCSs on 
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virulence gene expression or the involvement of BraRS and GraXRS in antibiotic resistance has been studied in 
great  detail7–10. Furthermore, since TCSs are a matter of life and death to bacteria and they are not present in host’s 
cells, these regulatory pathways have always been listed as promising antibacterial targets. Precisely based on the 
assumption that solution to present-day therapeutic limitations might somehow lie on impairing the way Staphy-
lococcus senses and integrates environmental stimuli, significant effort in the form of ambitious High Throughput 
Screenings (HTSs) and Structure-Based Virtual Screenings (SBVSs) has been done to find new molecules with 
inhibitory effects on staphylococcal sensor  kinases11. However, with few exceptions such as the molecule named 
walkmycin  B12, biochemical screens normally identify a high number of compounds acting through nonspecific 
inhibitory mechanisms and thus render non-viable drugs in terms of clinical  application11,13,14.
With the aim of designing a whole-cell drug discovery tool that could complement in silico docking and 
crystallographic analysis of kinase-ligands structure in TCS-targeting approaches, we decided to explore the 
potential of a recently developed staphylococcal strain that lacks the whole non-essential TCS machinery (∆XV 
strain)15. Among all the TCSs whose individual contribution to a specific S. aureus phenotype has been defined, 
and based on its overall responsibility for resistance to host defenses like polymorphonuclear cells (PMNs) or 
cationic antimicrobial peptides, we selected GraXRS as a candidate of therapeutic  target9,16–19. Additional evi-
dence supporting our choice was given by a recent work showing that S. aureus uses this regulatory system to 
sense and adapt to the acidified phagolysosome in  macrophages20, but also by several previous studies unveiling 
the potential of GraXRS to impact the bacterial capacity to colonize and survive on aortic valves in a rabbit endo-
carditis infection  model18 or to play a crucial function in a murine model of systemic  infection16. Most of these 
preceding articles conclude that mechanisms underlying GraXRS activity are related with changes in bacterial 
surface charge via its target downstream gene mprF and the operon dltABCD9,17,18,21.
In this study, we have used the S. aureus strain deprived of fifteen  TCS15 and isogenic derivatives contain-
ing exclusively the GraXRS TCS as a whole-cell platform to identify drugs that specifically target this signaling 
pathway. Upon evaluating the GraXRS-blocking activity of 1280 FDA-approved off-patent drugs, we found that 
molecules with antioxidant activity as acetylsalicylic acid, ascorbic acid, the porphyrin derivative verteporfin, 
or the flavonoid hesperidin, are capable of inhibiting the activity of GraXRS-dependent promoters. Among all 
the compounds, only verteporfin made a significant contribution to the susceptibility of S. aureus to human 
PMNs-mediated killing and rendered lower levels of bacterial colonization when its effect was assessed using 
an in vivo murine model. Though further analysis is needed to fully understand the precise molecular targets 
of verteporfin, data presented in this work suggest that the redox-active cysteine of GraS is required for this 
molecule to exert its inhibiting effect. Altogether, our results enlighten the potential of verteporfin as a supple-
ment and(or) alternative antimicrobial therapy and provide evidence that this compound could be included in 
a recently described category of drugs known as “Potential Drugs for Repurposing against Infectious Agents”.
Results
Design and validation of a GraXRS‑focused screening platform. With the aim of designing a 
highly specific GraXRS-targeting screening assay, we first restored the GraXRS TCS into the chromosome of S. 
aureus ΔXV strain, which only contains the essential WalKS TCS system in its genome. The resulting S. aureus 
ΔXV Gra-RES strain, together with the corresponding S. aureus MW2 wild type strain and the single GraXRS 
mutant derivative, were transformed with two different reporter plasmids in which lacZ expression depends 
on the GraXRS-regulated promoters of mprF and dltX9. As shown in Fig. 1, transcriptional activity of reporter 
genes was barely detectable in the GraXRS deficient strains (single and multiple ΔXV mutants), whereas mprF 
and dltX-based reporter constructs were highly induced in the GraXRS containing strains (wild type and ΔXV 
GraRES). As an additional test for evaluating the behavior of the reporter strain-set, positive response of the 
GraXRS-dependent promoters to the presence of sublethal concentrations of colistin was also analyzed. Noticea-
bly, and confirming the concept of TCS as self-sufficient modules previously  envisioned15, lacZ expression driven 
by dltX promoter was essentially equal in the wild type and graXRS restored genetic backgrounds. This result 
validates both the use of the GraXRS restored strain and dltXP::lacZ transcriptional fusion for high-throughput-
screening designs aimed at the discovery of GraXRS-blocking drugs and molecules.
Primary and secondary screenings. From the initial screening of the 1280 drugs included in the Prest-
wick library (https ://www.prest wickc hemic al.com/libra ries-scree ning-lib-pcl.html), we selected 77 compounds 
that led to reduced activity of dltX promoter by more than 55% as determined by beta-galactosidase activity (see 
table in the supplemental material). Because the intention of this work was to repurpose those FDA-approved 
drugs that specifically targeted GraXRS-mediated signaling pathway, and this TCS has been shown to be crucial 
for bacterial growth under acidic  conditions15, the capacity of the selected compounds to affect  OD600 values at 
pH 5.5 was tested, expecting a significant growth arrest in the presence of GraXRS-blocking compounds. Fol-
lowing a similar approach, the dose–response behavior of selected compounds was evaluated. To do so, both 
bacterial growth and dltxP transcriptional activity were quantitatively assessed in the presence of variable con-
centrations, ranging from 0 to 20 μM, of selected drugs (Fig. 2C).
In order to reinforce the involvement of GraXRS TCS in the phenotypic outcomes rendered by the drugs to 
be chosen, their ability to down regulate the GraXRS-dependent alternative mprF promoter was considered as 
an additional selective criterion.
To verify the specificity of GraXRS for the selected compounds, we restored a different TCS, saeRS, into the 
∆XV genome. In this case, the reporter lacZ gene was transcriptionally fused to sec4 promoter, which has previ-
ously described as part of SaeRS  regulon22. No shift in the transcription levels of sec4P::lacZ fusion appeared 
when ∆XV Sae-RES were incubated in the presence of each selected compound.
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Finally, and though equivalency between wild type and GraXRS restored strains in terms of GraXRS-mediated 
sensing had been previously validated, the possibility that other TCSs or derived circuits absent on ∆XV Gra-
RES could somehow affect dltX transcriptional activity was considered. In order to address this issue, the MW2 
wild type strain was transformed with the dltX-derived reporter plasmid and beta-galactosidase activity was 
measured in the absence and presence of mentioned compounds.
As shown in Fig. 2, the whole consecutive screening process significantly restricted the number of active 
compounds from almost 80 to 5. Acetylsalicylic acid (ASA), hesperidin (HES), ascorbic acid (VITC), verteporfin 
(VER) and troglitazone (TGZ) were capable of inhibiting bacterial growth under acidic conditions, affected 
mprFP activity negatively and exerted a suppressing effect on dltXP in the wild type genetic background. Among 
this final group of drugs, TGZ displayed an additional negative impact on SaeRS, and thus was firstly consid-
ered as a potential multi-target drug. However, since this molecule was withdrawn in 2000 due to high risk of 
hepatotoxicity, only ASA, HES, VITC and VER were contemplated as real candidates for therapeutic reposition. 
Curiously, though these four compounds show no common (known) pharmacological features, they are all 
chemically classified as redox-active drugs.
In vitro effect of selected compounds: phagocytosis and killing of S. aureus by human 
PMNs. Deepening into the anti-virulence potential of selected drugs, we next proceeded with an in vitro 
assay in which the bacterial susceptibility to phagocytosis and killing by human polymorphonuclear cells was 
assessed. Considering that GraXRS has been shown to have a pivotal role for S. aureus to resist PMN  attack20, 
we isolated this cellular fraction from peripheral human blood and the effect of ASA, HES, VITC and VER on 
MW2 susceptibility to these immune cells was assessed. In all cases the process was boosted by opsonic antibod-
ies naturally present in human sera due to unavoidable exposure to S. aureus. After incubating PMNs-S. aureus 
MW2 suspensions for 30 min in the absence or presence of the four selected compounds (5 μM each), removal 
of extracellular bacteria via gentamicin exposure, and subsequent lysis of eukaryotic cells at basic pH, bacterial 
viability was estimated via plate counting. Data shown in Fig. 3 prompted us to conclude that the presence of 
ASA, HES and VITC caused a slight increase in the sensitivity to PMN attack, while the effect of VER on reduc-
ing the number of surviving intracellular bacteria was substantially obvious and statistically significant (Fig. 3). 
As a result, from this in vitro approach, we chose VER as the sole candidate to proceed with the next assays.
Effect of verteporfin in a murine model of wound infection. Following on from the in vitro testing, 
we next evaluated VER using the murine model of wound (or surgical site) infection. In this in vivo approach, a 
silk suture contaminated with S. aureus MW2 or MW2ΔgraXRS strain (4.5 × 105 cfus cm−1) was used for sewing 
Figure 1.  Validation of GraXRS-dependent transcriptional fusions. Graphic illustration of GraXRS-dependent 
activity of dltX (A) and mprF (B) promoters in S. aureus MW2 wild type, ∆XV, ∆XV Gra-RES and ∆graRS 
strains. Transcriptional activity in TSB medium (light gray bars) and TSB supplemented with colistin 50 μg/ml 
(dark grey bars) is presented. Means and standard deviations values are shown from at least three independent 
experiments. A visual example showing different degrees of GraXRS activity [∆XV (1), ∆XV Gra-RES (2) and 
∆XV Gra-RES in the presence of colistin (3)] in the 96-well format is also shown.
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Figure 2.  Screening results. (A) Graphic illustration of GraXRS-dependent activity of dltX promoter in the presence of selected drugs 
(10 μM) in S. aureus ∆XV Gra-RES (light gray bars) and MW2 wild type strains (dark grey bars). Data are presented as relative M.U. 
values obtained in the absence of any compound for S. aureus ∆XV Gra-RES and MW2 wild type strains respectively. Values exceeding 
100% correspond to those cases where the observed transcriptional activity is lower to that showed by ∆XV and/or bacterial growth 
is inhibited. Standard deviations values correspond to at least three independent experiments. Results regarding additional selection 
criteria including the repression of the GraXRS-dependent alternative mprF promoter, significative inhibition of wild type strain under 
acidic growth conditions (pH 5.5) and transcriptional co-inhibition of the SaeRS-dependent sec4 promoter are presented. (B) Structure 
of selected drugs included in drug bank profiles (https ://www.drugb ank.ca) is shown. (C) Graphic illustration of Dose Dependency 
profiles in terms of dlxP inhibition exhibited by selected compounds. Data are presented as relative M.U. values obtained in the 
absence of any compound for S. aureus ∆XV Gra-RES (dark grey bars). Relative percentage of survival in the presence of increasing 
doses of compounds is also included (light grey bars).
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up a previous incision on the back of the mice. VER was topically applied 2 and 24 h after suture implantation 
using hydrogel-based formulations that contained either no active ingredient or the porphyrin under study at 
a low (0.125 mg/kg) or a high (2.5 mg/kg) dose. Assessment of the infection was performed by counting viable 
bacteria in tissue homogenates that were obtained upon animal euthanasia, 24 h after the last treatment.
As shown in Fig. 4, the significantly lower quantity of viable bacteria present in tissue samples that had been 
infected with the GraXRS deficient strain unveiled the critical role of this TCS in surgical wound infections. 
When the effect of VER was assessed, data showed that topical administration of this drug significantly reduced 
the bacterial load in a dose-dependent manner. Noticeably, application of VER at a low dose led to a similar 
degree of bacterial colonization to that followed by the implantation of sutures that had been contaminated with 
the GraXRS lacking strain. While such a result reinforces the potential of VER as a GraXRS inhibitory drug, its 
specificity is suggested by the fact that the observed outcome after treatment of wounds infected with the wild 
type strain is certainly evident but it becomes almost imperceptible in the case of ∆graXRS-associated infection. 
Equally certain, however, is that high doses of VER could exert a GraXRS-independent and/or antibiotic effect.
Exploring the mechanistic basis of verteporfin. Because VER is a tetradentate chelating  porphyrin23 
that might be involved in redox sensing, just like heme complex, and such molecules are normally sensed through 
thiol-based switches, we also analyzed the contribution of the single redox-active cysteine present in GraS, C227, 
to VER  effect24. To do so, C227 was mutated to S or A in ∆XV Gra-RES background and transcriptional activ-
ity of dltXP in the resulting ∆XV Gra-RES S(C227-S) and ∆XV Gra-RES S(C227-A) strains was measured. An 
additional strain in which GraS H129 amino acid, the residue that undergoes phosphorylation upon activation 
of the kinase, had been mutated to Q was also constructed and included as a reference of complete GraXRS inac-
tivation. As shown in Fig. 5A, data verified that replacement of cysteine by another residue had a negative impact 
on GraXRS activity, being such an outcome dependent on the polarity of the substituted amino acid. Thus, 
C227-A (non-polar) GraS isoform led to a lower degree of transcriptional activity of dltXP in comparison to that 
showed by the isoform in which C227 had been mutated to the polar amino acid serine. In accordance with this 
observation, bacterial growth arrest under acidic conditions, a phenotype that strictly reflects GraXRS status, 
also showed dependence on the mutation polarity (Fig. 5B). When the effect of VER was assessed, transcrip-
tional data revealed that GraXRS repression led by mutations was far from being as drastic as the one achieved 
by VER (Fig. 5A), discarding the possibility of considering the C227 redox switch as the exclusive mechanism 
underlying VER effect. However, impairment of the signaling via C227 resulted in the insensitivity to VER, fact 
that suggests that intermolecular cysteine-disulfide-bond formation is required, though not entirely, for VER to 
have a blocking GraXRS-dependent effect.
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Figure 3.  Effect of selected drugs in the susceptibility to phagocytosis and killing by human PMNs. Graphical 
scheme of bacterial counts expressed as log values after incubating PMNs and S. aureus MW2 wild type 
suspensions for 30 min in the presence or absence of four selected compounds (5 μM each), subsequent 
gentamicin treatments and lysis of eukaryotic cells (see “Materials and methods” section). Means and standard 
deviations are presented, illustrating the bactericidal effect of PMNs and the additional contribution of ASA, 
VITC, VER, TIR, DIA and HES. In the case of VER, two asterisks denote an associated p value of 0.006 when 
ANOVA and Tukey’s pairwise post hoc tests were applied according to prior normality and homoscedasticity 
tests.
6
Vol:.(1234567890)
Scientific Reports |        (2020) 10:17939  | https://doi.org/10.1038/s41598-020-74873-5
www.nature.com/scientificreports/
Lo
g 
C
FU
s 
/ g
r
S. aureus MW2 S. aureus MW2∆graRS
3
3,75
4,50
5,25
6
6,75
7,50
8,25
2,25
Unt
rea
ted VE
R
0,1
25 
mg
 kg
-1
VE
R
2,5
 mg
 kg
-1
Unt
rea
ted VE
R
0,1
25 
mg
 kg
-1
VE
R
2,5
 mg
 kg
-1
p<0,05
p<0,05
p= 0,069
p=0,159
p<0,01
p<0,05
Figure 4.  Effect of VER in a murine model of surgical wound infection. BOX-PLOT illustration (PAST 
statistical package) of bacterial counts expressed as log values per gram of wound tissue homogenates. Different 
treatments include the topical administration of hydrogel-based formulations with two doses (0.125 and 
2.5 mg kg−1) of VER, 2 and 24 h after making an incision that was immediately infected with a surgical suture 
contaminated with 4 × 105 CFUs of S. aureus MW2 wild type or ∆graXRS strain. Hydrogel without any active 
pharmaceutical ingredient was applied to control mice. All the animals were euthanized 24 h after the last 
treatment. Apart from visual interpretation in accordance to IQR overlapping, data were statistically analyzed 
via Kruskal–Wallis and post hoc Mann–Whitney test. Corrected p-values corresponding to relevant post hoc 
statistical comparisons are also shown.
Figure 5.  C227-mediated redox switch involvement in the sensitizing effect exerted by VER. (A) 
Transcriptional activity of GraXRS-dependent dltX promoter in S. aureus ∆XV Gra-RES, ∆XV Gra-RES 
S(C227-S), ∆XV Gra-RES S(C227-A) and ∆XV Gra-RES S(H129-Q) strains is illustrated both in the presence 
(dark grey bars) or absence (light gray bars) of VER (10 μM). Means and standard deviations values are shown 
form at least three independent experiments. (B) Pictures illustrating the capacity of serially-diluted suspensions 
of bacterial strains S. aureus MW2 wild type, ∆XV, ∆graRS, ∆XV Gra-RES, ∆XV Gra-RES S(C227-S), ∆XV Gra-
RES S(C227-A) and ∆XV Gra-RES S(H129-Q) to grow in neutral (left) and acidified (right) TSA medium are 
also included in this figure.
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Discussion
Current strategies aimed at antimicrobial discovery prioritize innovative concepts like alternative molecular 
mechanisms of action, new natural product sources, pro-drugs, or even approved compounds that were origi-
nally intended for other therapeutic indications, as it is the case of the present work (Statement of Antimicrobial 
drug discovery, EASAC-201425). Particularly speaking of S. aureus, and discarding the essential TCS WalKR/S 
as the antibiotic target per excelence, continuous efforts are being made toward the discovery of inhibitors of 
TCS involved in virulence and biofilm formation (for  review26–28). Impairment of these non-essential biological 
pathways has the advantage of requiring a lower plasmatic dose compared with a MIC, reducing the tendency 
to resistance and minimizing side effects on neutral and beneficial microbiota that colonize treated human or 
animal  hosts29. Up to date, several novel and previously approved drugs with the capacity to exert an inhibitory 
effect on Agr, SaeRS, and ArlRS TCSs have been described (for  review26–28) but, to our knowledge, GraXRS 
had never been considered as a target for disarming S. aureus. The involvement of this TCS in the resistance to 
antimicrobial peptides and macrophages had already been envisioned in several  occasions9,30,31, but it has just 
been recently proven that GraXRS is entirely responsible for the response to pH inside acidified macrophage 
 phagolysosomes15,20. These premises led us to consider GraXRS as a clear target to counteract S. aureus response 
to innate host immunity and impede replication of the pathogen in the acute stage of systemic infection.
Taking advantage of the S. aureus strain that lacks its complete sensorial TCS  network15, we developed a series 
of reporter strains that could be helpful for selecting compounds capable of blocking transcriptional activity of 
the GraXRS-dependent dltX promoter. Working with ∆XV Gra-RES strain gave us the opportunity to perform 
a bioassay where bacterial sensing entirely depends on GraXRS (and WalkRS), thus reducing the probability of 
selecting off-target drug candidates. Proof of this last claim is the fact that among selected drugs, only one of 
them (Troglitazone) displayed a GraXRS-SaeRS multi target effect.
At the time of deciding the type of compound to be tested for the identification of GraXRS inhibitors, we, 
as many other researchers, opted for the drug-repurposing approach. This strategy is based on the identifica-
tion of “off ” antimicrobial targets for drugs that were approved for other clinical  diseases29, hence bypassing 
the financial and regulatory barriers that have to be overcome to bring a drug to market. At present day, this 
concept of repurposing has gained renewed interest and a novel category of drugs known as “Potential Drugs 
for Repurposing against Infectious Agents” is exponentially  thriving32 By way of example, the old antimalarial 
drug chloroquine is being tested as SARS-CoV-2  inhibitor33. Though the precise mechanistic basis of their effect 
remains to be completely elucidated, current candidate PDRIAs targeting S. aureus SaeRS and/or AgrTCSs are 
floxuridine, streptozotocin and  diflunisal28,34,35.
The screening methodology applied here consisted in the analysis of changes in dltXP transcriptional activity, 
followed by several consecutive steps where additional criteria like the effect on an alternative GraXRS-dependent 
promoter, TCS-selectivity, or the determination of bacterial growth in the presence of selected drugs under acidic 
conditions were applied. The overall process ended up in the selection of five candidate drugs: acetylsalicylic 
acid (ASA), hesperidin (HES), ascorbic acid (VITC), verteporfin (VER) and troglitazone (TGZ). Curiously, all 
compounds are classified as redox-active drugs. While ASA, HES, VITC and TGZ are commonly sorted as anti-
oxidant molecules, VER can induce oxidative stress through the production of free radicals or be alternatively 
combined with soluble metals and display a redox potential similar to that showed by the heme  complex23. These 
observations are in agreement with the previously unveiled connection between GraXRS and oxidative stress, 
evidenced by the deciphering of the GraXRS regulon and the proved essentiality of this TCS in staphylococcal 
resistance to redox compounds like paraquat or  H2029. Furthermore, a recent RNA-seq transcriptomic approach 
has just corroborated the involvement of GraXRS, collectively with VraSR, SaeRS, MgrA, SigB or Fur, in the cell 
response to thiol-oxidative  stress36,37.
After proving that VER was the only compound really capable of sensitizing bacteria against the effect of 
human PMNs, this compound was further examined using a murine model of surgical wound infection. This 
model has been previously used to assess the effect of systemic and topical antimicrobial agents, finding a close 
correlation with efficacy in clinical trials with human subjects. Noticeably, our results provided further evidence 
concerning the critical role of GraXRS in skin and wound infections and insinuated a pharmaceutical potential 
of VER as a novel local treatment for S. aureus infections. Since bacterial count after the infection with the wild 
type strain and subsequent treatment with 0.125 mg kg−1 of VER was quite similar to that proceeding from 
the infection with a GraXRS negative strain, the effect exerted by the porphyrin derivative seems to be highly 
dependent on the activity of this TCS.
When the possible path(s) of how VER inhibits the activity of GraXRS was envisaged, we thought of VER as 
a heme-like porphyrin capable of binding iron in different oxidation  states23. Recent transcriptomic studies con-
ducted with the constitutively-active forms of staphylococcal kinases have unveiled the involvement of GraXRS 
in the regulation of heme synthase A (MW_RS05355;38), fact that led us to attach importance to the chemical 
mimicry between both molecules. Since porphyrins are normally involved in thiol-based molecular  switches24, 
the unique potentially redox-active residue in GraS, C227, was considered a potential molecular target of VER. 
To address this question, the impact of C227 mutations to S and A on GraXRS activity and VER sensitivity was 
assessed. To our knowledge, the results achieved in this work by punctual mutations of C227 have evidenced 
for the first time that this cytosol-located redox-active residue actually participates in GraS kinase activity. This 
line of reasoning, which has support from studies that have characterized other bacterial kinases like  AcrB39, 
showed that GraS degree of silencing depended on the polar nature of the amino acid that substituted C227 and 
suggested the involvement of this redox-switch as a potential molecular target concerning VER effect. However, 
and though C227 substitutions led to insensitivity to VER, the inhibitory outcome yielded by mutations was not 
as drastic as the one achieved by exposure to VER, suggesting that additional molecular paths must be involved 
in this process. An additional candidate that might be considered is Stk1, the unique serine-threonine kinase 
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which cross-phosphorylates  GraR40 and shows homology with OXR1, one of the recently discovered mammalian 
target of VER that, curiously, is also related to oxidative  stress41. However, in accordance with Fridman et al.40, 
we have verified that both Stk1 and GraS-mediated phosphorylation on GraR as T128, T130, T149 and D51 
respectively are equally required for full dltX expression (data not shown), fact that seriously complicates the use 
of our reporter systems when it comes to holding Stk1 accountable for intervening on VER effect.
Could VER be considered a viable antimicrobial candidate? Though we are fully aware that further in vitro 
and in silico studies helping to understand the whole molecular scenario underlaying VER effect and alternative 
in vivo approaches or definition of strategic dosages are some pending issues to claim a novel anti-virulence 
pharmaceutical indication for VER, we are convinced that this drug presents some strengths, apart from those 
inherent to anti-virulence drugs, that might be worth considering. In terms of pharmacology, for instance, VER 
excretion is dependent on hepatic function, while many antibiotics primarily undergo elimination via kidney 
filtration. Thus, VER could be administered to patients suffering from kidney disease, or to those who were being 
concomitantly treated with antibiotics that are prone to cause nephrotoxicity (e.g. vancomycin)42. On the other 
hand, though side effects associated to parenteral administration of VER include hypersensitivity reactions or 
blood pressure alteration, these symptoms have lower mean severity ratings in comparison to those showed by 
many antibiotics (ema.europa.eu/Find medicine/Human medicines/European public assessment reports). Finally, 
taking into account that we have also observed that VER-containing topical formulations are effective and that 
further studies might confirm that chemical mimicry between porphyrin derivatives and heme group could 
actually be harnessed for disarming S. aureus, our results may be considered as a step forward in re-proposing 
VER as a plausible alternative in combating antimicrobial resistance.
Materials and methods
Bacterial strains, plasmids, oligonucleotides and culture media. Bacterial strains, plasmids and 
oligonucleotides (purchased to IDT) are listed in Tables 1, 2 and 3 respectively. Escherichia coli XL1blue strain 
was grown in LB broth and LB agar. Staphylococcus aureus strains were grown on trypticase soy broth (TSB), 
trypticase soy agar (TSA), trypticase soy broth with 0.2% of glucose (TSB-glu), Mueller Hinton (MH) and 
B2 medium [1% casein hydrolysate, 2.5% yeast extract, 2.5% NaCl, 0.1%  K2HPO4, and 0.5% glucose (w/v)]. 
When required for growth or selection, medium was supplemented with 5-Bromo-4-Chloro-3-Indolyl β-d-
Galactopyranoside (XGal) and/or the appropriate antibiotic at the following concentrations: erythromycin (Eri) 
10 μg ml−1, ampicillin (Am) 100 μg ml−1, chloramphenicol (Clo) 10 μg ml−1 and 20 μg ml−1.
DNA manipulations. Plasmids were purified using NucleoSpin Plasmid kit (Macherey–Nagel) according 
to the protocol provided by the manufacturer. PCR fragments and enzymatic reactions were purified using 
Table 1.  Strains used in this study.
Strain Characteristics References
Escherichia coli
Xl1Blue Cloning strain (recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F′ proAB lacIqZ∆M15 Tn10 (Tetr)]) Stratagene
Staphylococcus aureus
RN4220 Restriction deficient transformation recipient 48
MW2 Community-acquired strain of MRSA isolated in 1998 in North Dakota, USA 49
MW2ΔgraRS Markerless mutation of graRS genes 15
ΔXV MW2 ∆hptRS ∆lytSR ∆graRS ∆saeRS ∆MW1208-MW1209 ∆arlRS ∆srrAB ∆phoPR ∆yhcSR ∆vraSR ∆agrBDCA ∆kdpDE ∆hssRS ∆nreBC ∆braRS
15
ΔXV Gra-RES Restored ΔXV::graRS strain This study
ΔXV Gra-RES S(C227-A) Restored ΔXV::graRS strain with C227-A single amino acid substitution in GraS This study
ΔXV Gra-RES S(C227-S) Restored ΔXV::graRS strain with C227-S single amino acid substitution in GraS This study
ΔXV Gra-RES S(H129-Q) Restored ΔXV::graRS with H129-Q single amino acid substitution in GraS This study
ΔXV Gra-RES ΔgraX Markerless mutation of graX in ΔXV Gra-RES strain This study
ΔXV Sae-RES Restored ΔXV::saeRS strain This study
MW2 mprFp MW2 carrying pSA14::mprFp;  EriR This study
MW2 dltXp MW2 carrying pSA14::dltXp;  EriR This study
MW2 sec4p MW2 carrying pSA14::sec4p;  EriR This study
ΔXV mprFp ΔXV carrying pSA14::mprFp;  EriR This study
ΔXV dltXp ΔXV carrying pSA14::dltXp;  EriR This study
ΔXV sec4p ΔXV carrying pSA14::sec4p;  EriR This study
ΔXV Gra-RES mprFp Restored ΔXV::graRS strain carrying pSA14::mprFp;  EriR This study
ΔXV Gra-RES dltXp Restored ΔXV::graRS strain carrying pSA14::dltXp;  EriR This study
MW2 ΔgraRS mprFp MW2 ΔgraRS carrying pSA14::mprFp  EriR This study
MW2 ΔgraRS dltXp MW2 ΔgraRS carrying pSA14::dltXp  EriR This study
ΔXV Sae-RES sec4p Restored ΔXV::SaeRS carrying pSA14::sec4p  EriR This study
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Table 2.  Plasmid used in this study.
Plasmid Characteristics References
pMAD E. coli–S. aureus shuttle vector with a thermosensitive origin of replication used for allelic replacement
45
pMAD::graRES pMAD plasmid containing the allele for chromosomal restoration of graRS TCS This study
pMAD::saeRES pMAD plasmid containing the allele for chromosomal restoration of saeRS TCS This study
pMAD:: ∆graX pMAD plasmid containing the allele for markerless deletion of graX gene This study
pMAD::graRES S(C227-A) pMAD plasmid containing the allele for chromosomal restoration of graRS S(C227-A) isoform This study
pMAD::graRES S(C227-S) pMAD plasmid containing the allele for chromosomal restoration of graRS S(C227-S) isoform This study
pMAD::graRES S(H129-Q) pMAD plasmid containing the allele for chromosomal restoration of graRS S(H120-Q) isoform This study
pSA14 pM4 derivative carrying the promoterless E.coli lacZ gene for constructing transcriptional fusions
9
pSA14::mprFp pSA14 containing the mprF promoter region 9
pSA14::dltXp pSA14 containing the dltX promoter region This study
pSA14::sec4p pSA14 containing the sec4 promoter region This study
Table 3.  Oligonucleotides used in this study.
Oligonucleotide Sequence
Restoration of TCS
gra-E GGG CCA TAA AAA GCC TCC AG
gra-F GTA GCT TCC GAC TTG TGA GCC 
gra-A (EcoRI) CCG GGA GCTC GAA TTC CAA ATA GAT ATT GCT GTA TTC TTT ATC GAC CCAAC 
gra-D (BamHI) GGG CGA TATC GGA TCC AAC GCC ACC TAA AAC ACT TTG TAC AC
G C227A Rv CTA ATA ATC ATA CGG CAC CAT TTT ATATC 
H C227A Fwd GAT ATA AAA TGG TGC CGT ATG ATT ATTAG 
G C227S Rv TCT AAT AAT CAT ACG AGA CCA TTT TAT ATC 
H C227S Fwd AGA TAT AAA ATG GTC TCG TAT GAT TAT TAG 
G H129-Q Rv GTT TTT ATG TCT TGC ACA AAT TCT G
H H129-Q Fwd CAG AAT TTG TGC AAG ACA TAA AAA C
sae-E AGT ACA ATT TGA TGA TGG TGT TGG TG
sae-F GAT TTC ACA GCA CCC CTA GC
sae-A (BamHI) GGG CGA TATC GGA TCC CAA AAG GGT TAT TTG AAT GGA TAG GC
sae-D (NotI) CCA TGG CAT GCA TCG CTG TTC ACA TAA CAC TAC AAA TCG C
graX A (BglII) CAC AGA TCT GGT TGG TTA TTG AGT GGT ACA TTT G
graX B (XhoI) CAC CTC GAG CTA AAA TAC TCC TTT AAA CTG TAA CC
graX C (XhoI) CAC CTC GAG GGT GAT ATG GAT GCA AAT AC
graX D GGA GGA TCC TTT CGA TTT GAT TTT TTT TGG TAA TAAG 
graX E GTT GTT ATG CGA TTC TGA TAC AAG 
graX F TGT TTC GAT TGC ACT ATC CATAC 
Reporter construction
pSA14-Fw TGG AAT TGT GAG CGG ATA AC
pSA14-Rv CTC TTC GCT ATT ACG CCA G
mprFp-Fw (PstI) CTG CTG CAG TAT AGA TAA CCA TAT TGT TC
mprFp-Rv (BamHI) GGA GGA TCC TGA TTC ATT TTT TCA CAT CA
dltXp-Fw (PstI) GGCTG CAG GCG CTG ATG ATA ATT CAA TAA 
dltXp-Rv (BamHI) CGGGA TCC GAT TTC ATA TTG CAC CTC TTA AAG 
sec4p-Fw (PstI) GGCTG CAG GAG TGT GAA TAT ATA AAC AATG 
sec4p-Rv (BamHI) GCGGA TCC TTA TTC ATT TTT ATC TCC TTC 
mprFp-GFP-Fw (SalI) GTC GTC GAC GTAT AGA TAA CCA TAT TGT TC
mprFp-GFP-Rv (KpnI) GGT GGT ACC TGA TTC ATT TTT TCA CAT CA
Complementation plasmid
graR Fw (KpnI) GGGGT ACC TCG AGA ATG ATA TTG GGT GAT ATG G
graR Rv (EcoRI) GGGAA TTC CAA ATT ATT CAT GAG CCA TATA 
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GeneJET Gel Extraction and DNA Cleanup Micro Kit (Thermo Scientific). FastDigest restriction enzymes, 
Rapid DNA ligation kit, Dreamtaq DNA polymerase and Phusion DNA polymerase were supplied by Thermo 
Scientific and used according to provided instructions. Sequence verification of PCR-amplified products and 
plasmid constructions was performed by Stab Vida. Transformation of Staphylococcus aureus was performed 
following previously standardized  protocols43,44.
Allelic exchange of chromosomal genes. To generate markerless deletions, two fragments of at least 
500 bp that flanked upstream (primers A and B, Table 3) and downstream fragments (primers C and D, Table 3) 
of the region to be deleted were amplified by PCR. Amplified products were digested using the corresponding 
restriction enzymes (Table 3), purified and cloned by ligation into pMAD shuttle vector. To restore individual 
TCSs into ∆XV chromosome, a fragment containing the two flanking regions used to generate the  deletion15 
and the original TCS sequence were amplified by PCR using chromosomal DNA from MW2 strain as template 
and oligonucleotide pair gra or sae 1–3. For restoration of the TCS with single amino acid substitutions at C227, 
graRS was amplified using MW2 chromosomal DNA as template and a two-step PCR protocol. First, the oligo-
nucleotides A and G or H were used for generating two overlapping PCR products, while a second amplification 
step with A and D oligonucleotides using both purified PCR products as templates generated graRS S(C227-A) 
and graRS S(C227-S) isoforms. Such DNA fragments were purified, digested with the corresponding enzymes 
(see Table 3) and inserted by ligation into the pMAD shuttle  vector45. Homologous recombination experiments 
were performed as previously  described46. Final plasmidless erythromycin sensitive white colonies were tested 
by PCR using primers E and F (Table 3).
Reporter plasmid construction. pSA14 was used for the construction of different reporter plasmids. Pro-
moter regions of mprF, dltX and sec4 were amplified by PCR using oligonucleotides described in Table 3. PCR 
fragments were purified and cloned into pSA14 through restriction enzymes to generate transcriptional fusion 
with lacZ. GraRS-dependent reporter plasmids were transformed via electroporation into S. aureus MW2, 
MW2ΔgraXRS, ΔX, ΔXV Gra-RES and ΔXV Gra-RESΔgraX, while plasmid harboring Sae-dependent sec4 pro-
moter was inserted into MW2, ΔXV and ΔXV Sae-RES strains. To analyze mprF, dltX and sec4 expression, ON 
cultures were chemically lysed beta-galactosidase activity was measured.
High throughput beta‑galactosidase‑based screening. Screening of the 1280 off-patent FDA-
approved drugs in Prestwick Chemical drug library (Prestwick Chemical) was based in a method for beta-
galactosidase assays in 96 well plates. Working solutions of the compounds were prepared in 50 μl of sterile 
distilled-deionized water at a concentration of 20 μM, and combined with 50 μl of a 1:30 dilution on 2 × TSB 
medium of an overnight (ON) culture of S. aureus strains, thus generating 100 μl of 1:60 cell dilution on 1 × TSB 
at a final concentration of 10 μM of each drug. Plates were incubated during 24 h at 37 °C and, upon incubation, 
 OD600nm was measured (Multiskan Go; Thermo Scientific). Bacterial cells were subsequently lysed by the addi-
tion of 100 μl  well−1 of Z buffer supplemented with lysostaphin (0.5 mg ml−1) during 2 h at 37 °C; Next, 30 μl 
 well−1 of Ortho-Nitrophenyl-beta-galactoside (ONPG, 4 mg ml-1) was added and, when required, the reaction 
was stopped with 100 μl  well-1 of 1 M  Na2CO3.  OD420 and  OD550 values were finally recorded for Miller Units 
calculation. Untreated reporter ∆XV-GraRES and ∆XV strains were included in every plate as internal controls. 
Experiments were carried out in triplicate.
Phagocytosis and killing of S. aureus by human PMNs. Phagocytosis and killing of S. aureus by 
human neutrophils in presence of selected compounds was determined as described  before47. Polymorphonu-
clear cells (PMNs) were isolated from healthy human heparinized-defibrinated blood (Seralab Logistics) using 
Ficoll-Plaque PREMIUM (GE-Healthcare) according to manufacturer’s protocol and resuspended at a final con-
centration of 1 × 107 PMNs  ml−1 in HBSS supplemented with human serum. S. aureus strains were cultured to 
the early stationary phase and 10 ml of culture were centrifuged, washed twice with sterile PBS and resuspended 
in Hank’s Balanced Salt Solution (HBSS) supplemented with human serum at a final concentration of 4 × 105 
bacteria  ml−1. Finally, 0.2 ml of PMNs solution was mixed with 0.2 ml of S. aureus solution and 600 μl of HBSS 
supplemented with human serum. Compounds were added at a final concentration of 5 μM. After incubation at 
37 °C for 30 min, each sample was treated with gentamicin 100 mg ml−1 and then 100 μl of each mixture were 
added to 1 ml of pH 11 solution. Finally, serial dilutions were plated on TSA to determine the number of colony-
forming units (CFU) in presence of the different compounds. All data were referred to initial CFU number.
Mouse infection model. The experimental animal study was reviewed and approved by the “Comité 
de Ética, Experimentación Animal y Bioseguridad” of the Universidad de Navarra-Centro de Investigación 
Médica Aplicada (CIMA). Work was carried out at the CIMA animal facility under the principles and guide-
lines described in the “European Directive 86/609/EEC” for the protection of animals used for experimental 
purposes. Six-week-old female Swiss mice (20–25 g) were obtained from ENVIGO and confined in groups of 6 
animals.
The model was performed as previously  described50. Briefly, 10 cm fragments of commercial brailed silk 
(TC-15, Lorca Marín) were contaminated with 4 × 106 CFU cm−1 of S. aureus MW2 or S. aureus MW2ΔgraXRS 
strains by immersion during 30 min. Fragments were then blotted- dried. One day prior to the experiment, the 
interscapular skin was shaved using a sharp razor. On the day of the infection, superficial wounds were produced 
on the exposed back surface though a longitudinal midline incision of 2 cm approximately. The skin of either 
side of the incision was retracted, and the wound was infected by stitching it with contaminated suture and a 
suturing needle. Wounds were topically treated 1 h and 8 h after infection with approximately 100 μl of hydrogel 
11
Vol.:(0123456789)
Scientific Reports |        (2020) 10:17939  | https://doi.org/10.1038/s41598-020-74873-5
www.nature.com/scientificreports/
formulations containing 0.125 and 2.5 mg/100 μl. The hydrogel base without any active substance was applied 
in the control group. Treatments were repeated 24 h after infection and mice were sacrificed 24 h after the last 
application. Finally, the wounded tissue was resected, homogenized in PBS, and dilution series of homogenates 
was plated on TSB agar for enumeration of CFU (output). After an overnight incubation at 37 °C, CFU gr of 
 tissue-1 were calculated and expressed as  log10.
Statistical analysis. Data generated by PMN-mediated killing assay were compared using ANOVA, apply-
ing Tukey’s pairwise as post hoc test. Data obtained from the bacterial counts in the murine model were treated 
and compared using Kruskal–Wallis test, Mann–Whitney pairwise and Dunn’s post hoc tests. All tests were 
two-sided, and the significance level was 5%. The statistical analysis was performed with Past and R softwares.
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